Accellix Presentation: CD34+ Hematopoietic Stem/Progenitor Cell Enumeration in Apheresis Collections Using a New Microfluidic Cartridge-Based Flow Cytometry Platform
Thursday, May 30, 2024 01:00 PM - 01:30 PM
Theatre B
Global Showcase Presentation
Presenter:
Successful hematopoietic reconstitution after stem cell transplantation depends on the dose of CD34+ stem/progenitor cells present in the transplanted grafts. CD34+ cell enumeration is a critical quality control (QC) assay performed during graft processing and characterization. Our Cellular Therapy Laboratory (CTL) relies on the institutional flow cytometry laboratory for such an assay. While highly reliable, the current workflow and turnaround time affects clinical practice through additional, potentially unnecessary procedures and CD34+ cell yields above collection targets, altogether causing increased resource and workforce utilization. We present initial data demonstrating the performance of a new CD34+ cell enumeration method using the automated Accellix platform, a new microfluidic cartridge-based flow cytometry platform that has the potential to improve the efficiency of QC within CTL. We demonstrate that Accellix’s CD34+ cell enumeration is comparable to the predicate method for relevant clinical parameters including CD34+ cell characterization, enumeration, and viability. The new method has the potential to improve QC efficiency by simple and rapid workflow, minimize human error by automation, and reduce the number of collection and processing procedures.
Session Objectives:
- Camelia Iancu Rubin, PhD, CABP, Director, Cellular Therapy Laboratory Professor, Department of Pathology, Molecular & Cell-Based Medicine, Icahn School of Medicine and Mount Sinai Hospital, United States
Successful hematopoietic reconstitution after stem cell transplantation depends on the dose of CD34+ stem/progenitor cells present in the transplanted grafts. CD34+ cell enumeration is a critical quality control (QC) assay performed during graft processing and characterization. Our Cellular Therapy Laboratory (CTL) relies on the institutional flow cytometry laboratory for such an assay. While highly reliable, the current workflow and turnaround time affects clinical practice through additional, potentially unnecessary procedures and CD34+ cell yields above collection targets, altogether causing increased resource and workforce utilization. We present initial data demonstrating the performance of a new CD34+ cell enumeration method using the automated Accellix platform, a new microfluidic cartridge-based flow cytometry platform that has the potential to improve the efficiency of QC within CTL. We demonstrate that Accellix’s CD34+ cell enumeration is comparable to the predicate method for relevant clinical parameters including CD34+ cell characterization, enumeration, and viability. The new method has the potential to improve QC efficiency by simple and rapid workflow, minimize human error by automation, and reduce the number of collection and processing procedures.
Session Objectives:
- Appreciate the importance of QC assays in the characterization (i.e. CD34+ cell enumeration) of hematopoietic stem/progenitor cell products used in hematopoietic stem cell transplantation.
- Understand how alternative approaches to CD34+ cell characterization and enumeration have the potential to improve the Cellular Therapy Laboratories workflow
SPONSORED BY:
